Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report

RATIONALE: Malignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of quality of life for patients is priority. However, there is no standard method for the treatment for pancreatic cancer-mediated MA. Apatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Lijun, Wang, Lei, Zhu, Panrong, Xia, Youyou, Qiao, Yun, Hui, Kaiyuan, Hu, Chenxi, Ren, Yan, Jiang, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708962/
https://www.ncbi.nlm.nih.gov/pubmed/29381963
http://dx.doi.org/10.1097/MD.0000000000008725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708962/
https://www.ncbi.nlm.nih.gov/pubmed/29381963
http://dx.doi.org/10.1097/MD.0000000000008725

Ejemplares similares